ClinicalTrials.gg
RecruitingNCT05758493Updated Apr 13, 2026

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

A Phase 2 interventional study of 124I-Evuzamitide in Amyloidosis and Transthyretin Amyloidosis, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Primary conditionAmyloidosis, Hereditary, Transthyretin-RelatedRegistry: AmyloidosisReclassifiedWhy we changed it
Registry
Amyloidosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Amyloidosis, Hereditary, Transthyretin-Related
Why
  1. The study's listed conditions name Amyloidosis, Hereditary, Transthyretin-Related, a narrower term within Amyloidosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Oregon Health and Science University · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States — 10 open to participants now, 12 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · United States.

Planned enrollment
11th of 23
150 · median 150
Started
2023
with 4 others
Phase 2
2 of 37
1 open now
Primary completion
2027-12
later than 4 of 11 live
Registered
30th of 37
by date

Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, this one is the 11th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2023, is one of 2 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 30th registered.

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Open to participants now

10 of the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, or all of them as a file.
02

Study summary

This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 4) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET/MRI). In a subgroup of patients who are unable to undergo PET/MR, computed tomography will be used instead of MRI (i.e. PET/CT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.

03

Conditions studied

  • Amyloidosis
  • Transthyretin Amyloidosis

Browse trials for

04

In context

Amyloidosis, Hereditary, Transthyretin-Related Reclassified

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

This study's planned enrollment of 150 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.

Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.

Compared within Amyloidosis, Hereditary, Transthyretin-Related, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Amyloidosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects will at least have one of the following conditions: systemic amyloidosis with known organ involvement, carrier of a known pathogenic mutation in the transthyretin gene, multiple myeloma, and monoclonal gammopathy of undetermined significance
  2. Patient willing to consent for the study and undergo the study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol
  2. Has a known allergy to potassium iodide treatment or to gadolinium.
  3. Patients on dialysis or those with \<30 cc/min/1.73 m2 will be excluded from undergoing gadolinium-enhanced cardiac MRI.
  4. Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 days prior to 124I-Evuzumitide administration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Patients with ATTR-CM

    Patients with ATTR-CM will undergo hybrid 124I-Evuzamitide PET/MRI imaging (or PET/CT) at baseline and in a subgroup, repeat imaging will be performed at an interval of 6-12 months.

    Diagnostic Test: 124I-Evuzamitide

Interventions

  • Diagnostic test124I-Evuzamitide

    Amyloid reactive protein used as imaging agent to detect systemic amyloidosis

    Also known as: AT-01

07

What researchers measure

Primary outcomes

  1. I-124 evuzamitide diagnostic accuracy

    To evaluate the efficacy of I-124 evuzamitide for diagnosing cardiac amyloidosis based on visual scan interpretation, compared to SoC site diagnosis. We will assess: * The sensitivity of PET/MRI with 124I-evuzamitide PET/MRI for the diagnosis of cardiac amyloidosis. * The specificity of PET/MRI with 124I-evuzamitide for the diagnosis of cardiac amyloidosis.

    Time frame: At baseline scan

Secondary outcomes

  1. Quantitative measures

    To evaluate the efficacy of I-124 evuzamitide for diagnosing cardiac amyloidosis based on quantitative scan interpretation, compared to SoC site diagnosis. We will assess the sensitivity and specificity of various quantitative measures, and evaluate inter- and intra-reader agreement.

    Time frame: At baseline scan

  2. Correlation between clinical cardiac biomarkers (i.e. stage of amyloidosis) and myocardial 124I-Evuzamitide uptake

    Pearson Correlation Coefficient of stage of amyloidosis (Mayo Staging System) and SUV (124I-Evuzamitide)

    Time frame: At baseline scan

  3. Correlation between Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS) and myocardial 124I-Evuzamitide

    Time frame: During baseline scan and follow up scan

  4. Correlation between New York Heart Association (NYHA) class and 124I-Evuzamitide uptake

    Time frame: During baseline scan and follow up scan

  5. Correlation between liver and spleen ECV and their respective 124I-Evuzamitide uptake

    Time frame: During baseline scan and follow up scan

  6. Proportion of patients with ATTR-CM and MGUS or smoldering myeloma who are correctly classified as ATTR-CM based on 124I-Evuzamitide distribution and uptake

    Time frame: During baseline scan

  7. To evaluate the safety of a single intravenous administration of I-124 evuzamitide.

    Incidence of related treatment-emergent (S)AEs from time of study drug administration to Day 7

    Time frame: 7 days from baseline scan

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Wall JS, Martin EB, Endsley A, Stuckey AC, Williams AD, Powell D, Whittle B, Hall S, Lambeth TR, Julian RR, Stabin M, Lands RH, Kennel SJ. First in Human Evaluation and Dosimetry Calculations for Peptide 124I-p5+14-a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET/CT Imaging. Mol Imaging Biol. 2022 Jun;24(3):479-488. doi: 10.1007/s11307-021-01681-2. Epub 2021 Nov 16. PubMed 34786667 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Mar 7, 2023
StartActual
Jan 10, 2023
Primary completionEst.
Dec 10, 2027
CompletionEst.
Mar 10, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05758493
Collaborators
Attralus, Inc., Bayer
Responsible party
Ahmad Masri (Associate Professor, Oregon Health and Science University) — Principal investigator
First posted
Mar 7, 2023
Start date
Jan 10, 2023
Primary completion
Dec 10, 2027 (estimated)
Completion
Mar 10, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Ahmad Masri, MD
Contact
masria@ohsu.edu
503-418-1964

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion